Bioactive Glass Shown Effective Towards Antibiotic-resistant Bacteria

By Julie A. Vetalice

Studies of BonAlive® indicate that the naturally-antibacterial bioactive glass yields excellent results in the treatment of osteomyelitis, without the use of local antibiotics.

The 116-patient study was conducted in Azerbaijan, Finland, Germany, Italy, the Netherlands and Poland; 90% of patients made a full recovery. Most had previously undergone numerous procedures, sometimes for decades.

BonAlive's S53P4 bioactive glass bone graft substitute is intended to stimulate new bone growth and protect the surgical site from bacterial growth. BonAlive granules have been cleared for orthopaedic applications since 2006 and for bone cavity filling in the treatment of chronic osteomyelitis since 2011. A ready-to-use, moldable version of BonAlive received CE Mark approval in 2013.

The product has application in adult and pediatric neuro, trauma, orthopaedic and ear surgery, and in 2016 alone was used in ~10,000 procedures globally.

Study results were published in Advances in Experimental Medicine and Biology, January 2017.

Sources: BonAlive Biomaterials Ltd; ORTHOWORLD Inc.


Product Labels: Synthetic Bone Graft

Tags: Trial/Study